Partial Response

Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma
Ashwin Chandar, Ann W Silk, Joseph I Clark, Gregory A Daniels, David F McDermott, Michael Morse, Michael KK Wong, Mark Stein, Janice Mehnert, Shabbar Danish, Sandra Aung, Howard L Kaufman

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P129; DOI: 10.1186/2051-1426-3-S2-P129
Comparative study of sequential intravesical chemotherapy using gemcitabine and mitomycin C with mitomycin C alone for non-muscle invasive bladder carcinoma- a randomized trial
Kumar Jayant, Santosh Kumar, Shrawan kumar Singh, Swati Agrawal, Rajendra Agrawal

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P136; DOI: 10.1186/2051-1426-3-S2-P136
Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients
Antonio Maria Grimaldi, Ester Simeone, Lucia Festino, Diana Giannarelli, Marco Palla, Corrado Caracò, Marcello Curvietto, Assunta Esposito, Maria Chiara Grimaldi, Nicola Mozzillo, Paolo A Ascierto

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P186; DOI: 10.1186/2051-1426-3-S2-P186
The role of surgery following incomplete response to high-dose IL-2 (HD IL-2)
Tasha Hughes, Gail Iodice, Sanjib Basu, Steven Bines, Howard Kaufman

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P145; DOI: 10.1186/2051-1426-1-S1-P145

Main menu